The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstream targets

Journal of Clinical Investigation

Volumn 100, Issue 4, 1997, Pages 875-885

  Bornfeldt, Karin E ^a,b   Campbell, Jean S ^b   Koyama, Hidenori ^a   Argast, Gretchen M ^b   Leslie, Christina C ^c   Raines, Elaine W ^a   Krebs, Edwin G ^b   Ross, Russell ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Cyclooxygenase; Human; Phospholipase; Platelet derived growth factor; Prostaglandin E

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE A2; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E2; PROTEIN KINASE INHIBITOR;

ADULT; ARTERY MUSCLE; ARTICLE; CELL PROLIFERATION; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEWBORN; PRIORITY JOURNAL;

EID: 0030823407     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119603     Document Type: Article

References (63)

1. Seger, R., and E.G. Krebs. 1995. The MAPK signaling cascade. FASEB (Fed. Am. Soc. Exp. Biol.) J. 9:726-735.
2. Whitmarsh, A.J., P. Shore, A.D. Sharrocks, and R.J. Davis. 1995. Integration of MAP kinase signal transduction pathways at the serum response element. Science (Wash. DC). 269:403-407.
3. Davis, R.J. 1993. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:14553-14556.
4. Dennis, E.A. 1994. Diversity of group types, regulation, and function of phospholipase A2. J. Biol. Chem. 269:13057-13060.
5. Kramer, R.M. 1995. In Signal-Activated Phospholipases. M. Liscovitch, editor. R.G. Landes Company, Austin, TX. 13-30.
6. Boulton, T.G., G.D. Yancopoulos, J.S. Gregory, C. Slaughter, C. Moomaw, J. Hsu, and M.H. Cobb. 1990. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science (Wash. DC). 249: 64-67.
7. Cowley, S., H. Paterson, P. Kemp, and C.J. Marshall. 1994. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 77:841-852.
8. Seger, R., D. Seger, A.A. Reszka, E.S. Munar, H. Eldar-Finkelman, G. Dobrowolska, A.M. Jensen, J.S. Campbell, E.H. Fischer, and E.G., Krebs. 1994. Over-expression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH-3T3 cells: evidence that MAPKK's involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. J. Biol. Chem. 269:25699-25709.
9. Lai, K., H. Wang, W.-S. Lee, M.K. Jain, M.-E. Lee, and E. Haber. 1996. Mitogen-activated protein kinase phosphatase-1 in rat arterial smooth muscle cell proliferation. J. Clin. Invest. 98:1560-1567.
10. Mansour, S. J., W.T. Matten, A.S. Hermann, J.M. Candia, S. Rong, K. Fukasawa, G.F. Van de Woude, and N.G. Ahn. 1994. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science (Wash. DC). 265:966-970.
11. Traverse, S., N. Gomez, H. Paterson, C. Marshall, and P. Cohen. 1992. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem. J. 288:351-355.
12. Chen, Q., M.S. Kinch, T.H. Lin, K. Burridge, and R.L. Juliano. 1994. Integrin-mediated cell adhesion activates mitogen-activated protein kinases. J. Biol. Chem. 269:26602-26605.
13. Adam, L.P., M.T. Franklin, G.J. Raff, and D.R. Hathaway. 1995. Activation of mitogen-activated protein kinase in porcine carotid arteries. Circ. Res. 76:183-190.
14. Servant, M.J., E. Giasson, and S. Meloche. 1996. Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells. J. Biol. Chem. 271:16047-16052.
15. Dudley, D.T., L. Pang, S.J. Decker, A.J. Bridges, and A.R. Saltiel. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA. 92:7686-7689.
16. Alessi, D.R., A. Cuenda, P. Cohen, D.T. Dudley, and A.R. Saltiel. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489-27494.
17. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (Lond.). 362:801-809.
18. Ross, R., and B. Kariya. 1980. Circulation, vascular smooth muscle. In Handbook of Physiology - The Cardiovascular System. D.F. Bohr, A.P. Somlyo, and V. Sparks, editors. American Physiological Society, Bethesda, MD. 69-91.
19. Raines, E.W., D.F. Bowen-Pope, and R. Ross. 1990. Peptide growth factors and their receptors. In Handbook of Experimental Pharmacology. M.B. Sporn and A.B. Roberts, editors. Vol. 951. Springer-Verlag New York Inc., New York. 173-262.
20. Bornfeldt, K.E., E.W. Raines, T. Nakano, L.M. Graves, E.G. Krebs, and R. Ross. 1994. Insulin-like growth factor I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J. Clin. Invest. 93: 1266-1274.
21. Graves, L.M., K.E. Bornfeldt, E.W. Raines, B.C. Potts, S.G. MacDonald, R. Ross, and E.G., Krebs. 1993. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc. Natl. Acad. Sci. USA. 90:10300-10304.
22. Seger, R., N.G. Ahn, J. Posada, E.S. Munar, A.M. Jensen, J.A. Cooper, M.H. Cobb, and E.G., Krebs. 1992. Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J. Biol. Chem. 267:14373-14381.
23. Libby, P., S.J.C. Warner, and G.B. Friedman. 1988. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J. Clin. Invest. 81:487-498.
24. Graves, L.M., K.E. Bornfeldt, J.S. Sidhu, G.M. Argast, E.W. Raines, R. Ross, C.C. Leslie, and E.G., Krebs. 1996. Platelet-derived growth factor stimulates protein kinase A through a mitogen-activated protein kinase dependent pathway in human arterial smooth muscle cells. J. Biol. Chem. 271:505-511.
25. Raines, E.W., S.K. Dower, and R. Ross. 1989. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science (Wash. DC). 243:393-396.
26. Fujitani, Y., H. Ninomiya, T. Okada, Y. Urade, and T. Masaki. 1995. Suppression of endothelin-1-induced mitogenic responses of human aortic smooth muscle cells by interleukin-1 β. J. Clin. Invest. 95:2474-2482.
27. 1. Exp. Cell Res. 160:117-125.
28. 2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. Biochem J. 288:527-532.
29. Hultgardh-Nilsson, A., V. Querol-Ferrer, B. Jonzon, U. Krondahl, and J. Nilsson. 1994. Cyclic AMP, early response gene expression, and DNA synthesis in rat smooth muscle cells. Exp. Cell Res. 214:297-302.
30. Fukuo, K., S. Morimoto, B. Jiang, T. Inoue, T. Nabata, and T. Ogihara. 1994. Elastase enhances cAMP accumulation and the inhibition of DNA synthesis induced by OP-41483, a stable prostacyclin analogue, in vascular smooth muscle cells. Atherosclerosis. 110:111-117.
31. Cook, S.J., and F. McCormick. 1993. Inhibition by cAMP of Ras-dependent activation of Raf. Science (Wash. DC). 262:1069-1072.
32. Sevetson, B.R., X. Kong, and J.C. Lawrence, Jr. 1993. Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc. Natl. Acad. Sci. USA. 90:10305-10309.
33. Wu, J., P. Dent, T. Jelinek, A. Wolfman, M.J. Weber, and T.W. Sturgill. 1993. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science (Wash. DC). 262:1065-1069.
34. Graves, L.M., K.E. Bornfeldt, G.M. Argast, E.G. Krebs, X. Kong, T.A. Lin, and J.C. Lawrence, Jr. 1995. cAMP-and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-1 in aortic smooth muscle cells. Proc. Natl. Acad. Sci. USA. 92:7222-7226.
35. Monfar, M., K.P. Lemon, T.C. Grammer, L. Cheatham, J. Chung, C.J. Vlahos, and J. Blenis. 1995. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. Mol. Cell. Biol. 15:326-337.
36. Gagelin, C., M. Pierre, and D. Toru-Delbauffe. 1994. Inhibition of G1 cyclin expression and G1 cyclin-dependent protein kinases by cAMP in an astrocytic cell line. Biochem. Biophys. Res. Commun. 205:923-929.
37. Kato, J.Y., M. Matsuoka, K. Polyak, J. Massague, and C.J. Sherr. 1994. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell. 79:487-496.
38. Duff, J.L., M.B. Marrero, W.G. Paxton, B. Schieffer, K.E. Bernstein, and B.C. Berk. 1995. Angiotensin II signal transduction and the mitogen-activated protein kinase pathway. Cardiovasc. Res. 30:511-517.
39. Tseng, H., T.E. Peterson, and B.C. Berk. 1995. Fluid shear stress stimulates mitogen-activated protein kinase in endothelial cells. Circ. Res. 77:869-878.
40. Xu, Q., Y. Liu, M. Gorospe, R. Udelsman, and N.J. Holbrook. 1996. Acute hypertension activates mitogen-activated protein kinases in arterial wall. J. Clin. Invest. 97:508-514.
41. Marshall, C.J. 1995. Opportunities for pharmacological intervention in the ras pathway. Annals of Oncology. 6(Suppl. 1):63-67.
42. Gould, G.W., A. Cuenda, F.J. Thomson, and P. Cohen. 1995. The activation of distinct mitogen-activated protein kinase cascades is required for the stimulation of 2-deoxyglucose uptake by interleukin-1 and insulin-like growth factor-1 in KB cells. Biochem. J. 311:735-738.
43. Lin, T.A., X. Kong, A.R. Saltiel, P.J. Blackshear, and J.C. Lawrence, Jr. 1995. Control of PHAS-I by insulin in 3T3-L1 adipocytes. Synthesis, degradation, and phosphorylation by a rapamycin-sensitive and mitogen-activated protein kinase-independent pathway. J. Biol. Chem. 270:18531-18538.
44. Levitzki, A., and A. Gazit. 1995. Tyrosine kinase inhibition: an approach to drug development. Science (Wash. DC). 267:1782-1788.
45. Vane, J.R., and R.M. Botting. 1995. New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res. 44:1-10.
46. De Witt, D.L., and W.L. Smith. 1995. Yes, but do they still get headaches? Cell. 83:345-348.
47. Lee, S.H., E. Soyoola, P. Chanmugam, S. Hart, W. Sun, H. Zhong, S. Liou, D. Simmons, and D. Hwang. 1992. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 267:25934-25938.
48. Karim, S., A. Habib, S. Lévy-Toledano, and J. Maclouf. 1996. Cyclooxygenases-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J. Biol. Chem. 271: 12042-12048.
49. Dinchuk, J.E., B.D. Car, R.J. Focht, J.J. Johnston, B.D. Jaffee, M.B. Covington, N.R. Contel, V.M. Eng, R.J. Collins, P.M. Czerniak, et al. 1995. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature (Lond.). 378:406-409.
50. Langenbach, R., S.G. Morham, H.F. Tiano, C.D. Loftin, B.I. Ghanayem, P.C. Chulada, J.F. Mahler, C.A. Lee, E.H. Goulding, K.D. Kluckman, et al. 1995. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 83:483-492.
51. Morham, S.G., R. Langenbach, C.D. Loftin, H.F. Tiano, N. Vouloumanos, J.C. Jennette, J.F. Mahler, K.D. Kluckman, A. Ledford, C.A. Lee, and O. Smithies. 1995. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 83:473-482.
52. Serhan, C.N., J.Z. Haeggström, and C.C. Leslie. 1996. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB (Fed. Am. Soc. Exp. Biol.) J. 10:1147-1158.
53. Pritchard, K.A., Jr., M.K. O'Banion, J.M. Miano, N. Vlasic, U.G. Bhatia, D.A. Young, and M.B. Stemerman. 1994. Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo. J. Biol. Chem. 269:8504-8509.
54. Rimarachin, J.A., J.A. Jacobson, P. Szabo, J. Maclouf, C. Creminon, and B.B. Weksler. 1994. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler. Thromb. 14:1021-1031.
55. 2 synthesis in mouse osteoblasts cultured with interleukin-1. J. Biol. Chem. 272:5952-5958.
56. Majesky, M.W., C.M. Giachelli, M.A. Reidy, and S.M. Schwartz. 1992. Rat carotid neointimal smooth muscle cells reexpress a developmentally regulated mRNA phenotype during repair of arterial injury. Circ. Res. 71:759-768.
57. Karlsson, C., and Y. Paulsson. 1994. Age related induction of platelet-derived growth factor A-chain mRNA in human fibroblasts. J. Cell. Physiol. 158:256-262.
58. Pumiglia, K.M., and S.J. Decker. 1997. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA. 94:448-452.
59. Marshall, C.J. 1995. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 80:179-185.
60. Hill, C.S., and R. Treisman. 1995. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell. 80:199-211.
61. Chan, C.-C., S. Boyce, C. Brideau, A.W. Ford-Hutchinson, R. Gordon, D. Guay, R.G. Hill, C.-S. Li, J. Mancini, M. Penneton, et al. 1995. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 274:1531-1537.
62. Futaki, N., S. Takahashi, M. Yokoyama, I. Arai, S. Higuchi, and S. Otomo. 1994. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 47:55-59.
63. Vago, T., M. Bevilaqua, and G. Norbiato. 1995. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneim.-Forsch. 45:1096-1098.